Monday 11 July 2011

Australian Securities Exchange Announcement

IMPEDIMED MAJOR MILESTONE - FIRST COVERED LIVES

ImpediMed announces first 12 million covered lives coverage from health and workers’ compensation benefits programs that cover L-Dex testing to aid in the clinical assessment of unilateral lymphoedema of the arms for female breast cancer patients.

Brisbane, Australia – ImpediMed Limited ("ImpediMed" or the “Company”) announces that it has now verified in the US market the first covered lives through a health benefits program for federal employees. This insurance program is reimbursing medical providers for L-Dex® testing to aid in the clinical assessment of unilateral lymphoedema of the arms for female breast cancer patients. There are ~ 9 million federal employees, retirees and family members that are covered under this program.

Initial ‘Explanations of Benefits’ (EOB) statements for U.S. medical provider’s treating federal employee members shows a reimbursement payment within the expected range of the economic model.

The health plan is an insurance benefits program for federal employees. The program is carried out by over 300 local insurance providers / health plans across the U.S.

In addition, ImpediMed Limited informs shareholders and investors today that it has now verified a further 3 million covered lives through the U.S. Federal Employees’ Compensation Act that provides workers’ compensation coverage to three million federal and postal workers around the world for employment-related injuries and occupational diseases as directed by the U.S. Department of Labor. This insurance program is reimbursing medical providers for L-Dex testing to aid in the clinical assessment of unilateral lymphoedema of the arms for female breast cancer patients who have undergone mastectomy and partial mastectomy treatments. The Department of Labor is a U.S. federal agency.

ImpediMed’s L-Dex U400 device is built on a bioimpedance spectroscopy (BIS) platform. BIS has regulatory marketing clearance on three continents and has access to a CPT category III code in the U.S. market for physicians billing the procedure. One accreditation program for breast centers within the United States has recently established a clinical standard for lymphedema risk reduction and management. Their recommendation supports the establishment of baseline assessment prior to surgery and post-surgical monitoring at each subsequent patient visit.

ImpediMed continues to be focused on building further coverage for L-Dex testing over the coming months. The Company reiterates its confidence in meeting the 20 million covered lives milestone by the end of this calendar year.

5735201/1
ImpediMed Limited
Unit 1, 50 Parker Court
Pinkenba, QLD 4008
Phone : +61-7-3860-3700

ASX CODE: IPD
ENDS
For further information contact:

Greg Brown
ImpediMed CEO
T: 61-7-3860-3700
Mobile/Cell: +61408281127

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

This announcement has been prepared for publication in Australia and New Zealand and may not be distributed or released in the United States. This announcement does not constitute promotion for the use of BIS devices in the United States or in any other jurisdiction in which such device clearance has not been obtained.